AtriCure: revenue up 15%, adjusted EBITDA up 50.6%, full-year guidance raised
AtriCure reported third-quarter revenue growth of 15% and adjusted EBITDA growth of 50.6%, and raised its 2026 guidance, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
AtriCure reported that third-quarter revenue grew 15%, while adjusted EBITDA rose 50.6%. Strength in U.S. franchises was the main driver of the results.
The company raised its FY2026 adjusted EBITDA guidance to $91M-$94M. Hybrid ablation and international markets still weigh on the outlook. The information comes from TradingView.
why it matters
A higher guidance figure typically supports investor interest in the stock, but weakness in hybrid ablation and overseas sales limits the upside. For small medtech companies, reports like this often set share price direction for the following weeks.
market impact
ATRC: higher guidance supports the shares, weak overseas sales limit the gains
- ATRC shares pressure up — raised EBITDA guidance and strong revenue growth support interest in the stock
tags
instruments
sources
- ATRC: Revenue grew 15%, adjusted EBITDA rose 50.6%, and FY guidance increased — TradingView, 3 November 2026 at 23:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗